Aug 19, 2021 — 3 min read
Using Intel® Distribution of OpenVINO™ Toolkit, Lunit’s AI solution for analyzing chest X-ray (Lunit INSIGHT CXR) can be applied in clinical sites that lack resources
The collaboration allows CPU-based processing of large-volume medical data, comparable to GPU performance
Lunit will expand the application of its AI software for analyzing chest X-ray, Lunit INSIGHT CXR, for CPU-based clinical sites. The AI has been available mostly for GPU-based sites, but with Intel® Distribution of OpenVINO™ Toolkit, it will be accessible to clinical sites struggling from limited resources.
A key benefit of AI-based medical imaging, such provided by Lunit INSIGHT CXR, is the ability to process medical images quickly and minimize the time from X-ray imaging to diagnosis. However, due to the limitations of traditional hardware, there are several technology hurdles addressed to the solution providers. Most CPUs don’t have the processing power to complete imaging analysis quickly enough to be effective, which leads to the slowdown of the processing.
Many existing AI-based medical imaging solutions employ a dedicated graphics processing unit (GPU) to increase processing speeds. These specialized processors are designed to accelerate graphics rendering and process many pieces of data simultaneously. While well suited for machine learning and imaging applications, GPU-based solutions are expensive, making them less viable for many healthcare organizations.
“To overcome the relatively higher cost of GPU-based imaging solutions, our team applied Intel Distribution of OpenVINO toolkit to improve the performance of more cost-effective CPU-based alternatives to discrete GPUs,” said Sunggyun Park, Chief Product Officer of Lunit.
“OpenVINO enables developers to optimize, tune, and run comprehensive AI inference applications faster,” said Ryan Kim, Medical Healthcare AI Business Lead of Intel Korea. “The toolkit can run inference workloads across almost any mix of Intel® processors and accelerators and enhances the performance of Lunit INSIGHT CXR on CPU-based systems, making the Lunit solution viable and more accessible for cost-constrained healthcare providers.”
Lunit INSIGHT CXR provides AI-powered detection of lesions that are suspicious of chest abnormalities with 97-99% accuracy, covering 10 most common findings on chest X-ray. It is CE marked and clinically applied in around 300 hospitals and healthcare institutions of more than 30 countries, supporting medical professionals to more efficiently diagnose chest diseases including COVID-19 symptoms.
“Based on Intel’s best-in-class technology, we have achieved inference speeds comparable to those produced on dedicated GPU solutions. The lower hardware cost of our CPU-based AI solution represents a compelling return on investment for Lunit’s distribution partners and for cost-conscious healthcare organizations looking to adopt an AI medical imaging solution,” added Park.
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Lunit preps Korean IPO led by NH Investment Bank
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021